Skip to main content

Fiscal Wizard · Single-issue tearsheet

GMAB / Jun 22, 2026 Run #7695

GMAB

Genmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Composite verdict

B 62.1 / 100
Bearish setup · Trend Following 13 drivers · gates clear
  • Accumulation/Distribution Line
  • Chaikin Money Flow
  • Parabolic SAR Flip
  • Coppock Curve
  • Engulfing
  • Trendline Break
Consider long put target Δ ~0.50 · ~35 DTE Bearish setup, Grade C → ITM put target

Industry rank 43rd of 598 in Biotechnology

rescore-sweep
Technical synthesis
Bull 33%Evidence: Low · 38 signals67% Bear
Momentum Bearish 33Mean-reversion Neutral 52

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -57%
Asset value $9.52Earnings power value $12.05Price $25.27

Priced above its no-growth earnings power value ($12.05/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Strong

82.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Inventory Turnover 100
Margin of Safety 0
Greenblatt ROC 93
Days Sales Outstanding 0
Free Cash Flow Yield 90
Earnings Yield 24

Technicals Neutral

41.3 / 100

Mixed setup — bull and bear signals both survive the gates. No clean directional edge. · 43 signals shown.

Strongest
Weakest
Accumulation/Distribution Line 93
Engulfing 13
Chaikin Money Flow 89
Coppock Curve 14
Parabolic SAR Flip 88
Trendline Break 16

Risk Gates

0 blocking 11 caution

No active guards. 11 caution flags (visual only).

Altman Z-Score Caution

Bottom-band Altman Z blocks bullish signals — distress risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Debt-to-Assets Caution

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Debt-to-Equity Caution

High debt-to-equity blocks bullish signals — leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for GMAB.